MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.

Saved in:
Bibliographic Details
Title: MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
Authors: Chien AJ; University of California, San Francisco, San Francisco, CA., Tripathy D; The University of Texas, MD Anderson Cancer Center, Houston, TX., Albain KS; Loyola University, Chicago, IL., Symmans WF; The University of Texas, MD Anderson Cancer Center, Houston, TX., Rugo HS; University of California, San Francisco, San Francisco, CA., Melisko ME; University of California, San Francisco, San Francisco, CA., Wallace AM; University of California, San Diego, La Jolla, CA., Schwab R; University of California, San Diego, La Jolla, CA., Helsten T; University of California, San Diego, La Jolla, CA., Forero-Torres A; University of Alabama at Birmingham, Birmingham, AL., Stringer-Reasor E; University of Alabama at Birmingham, Birmingham, AL., Ellis ED; Swedish Cancer Institute, Seattle, WA., Kaplan HG; Swedish Cancer Institute, Seattle, WA., Nanda R; The University of Chicago Medical Center, Chicago, IL., Jaskowiak N; The University of Chicago Medical Center, Chicago, IL., Murthy R; The University of Texas, MD Anderson Cancer Center, Houston, TX., Godellas C; Loyola University, Chicago, IL., Boughey JC; Mayo Clinic, Rochester, MN., Elias AD; University of Colorado Denver, Denver, CO., Haley BB; University of Texas Southwestern, Dallas, TX., Kemmer K; Oregon Health & Science University, Portland, OR., Isaacs C; Georgetown University, Washington, DC., Clark AS; University of Pennsylvania, Philadelphia, PA., Lang JE; University of Southern California, Los Angeles, CA., Lu J; University of Southern California, Los Angeles, CA., Korde L; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD., Edmiston KK; Inova Health System, Falls Church, VA., Northfelt DW; Mayo Clinic, Scottsdale, AZ., Viscusi RK; University of Arizona, Tucson, AZ., Yee D; Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Perlmutter J; Gemini Group, Bad Axe, MI., Hylton NM; University of California, San Francisco, San Francisco, CA., Van't Veer LJ; University of California, San Francisco, San Francisco, CA., DeMichele A; University of Pennsylvania, Philadelphia, PA., Wilson A; Quantum Leap Healthcare Collaborative, San Francisco, CA., Peterson G; University of California, San Francisco, San Francisco, CA., Buxton MB; Berry Consultants, Austin, TX., Paoloni M; Berry Consultants, Austin, TX., Clennell J; Berry Consultants, Austin, TX., Berry S; Berry Consultants, Austin, TX., Matthews JB; University of California, San Francisco, San Francisco, CA., Steeg K; University of California, San Francisco, San Francisco, CA., Singhrao R; University of California, San Francisco, San Francisco, CA., Hirst GL; University of California, San Francisco, San Francisco, CA., Sanil A; Berry Consultants, Austin, TX., Yau C; University of California, San Francisco, San Francisco, CA., Asare SM; Quantum Leap Healthcare Collaborative, San Francisco, CA., Berry DA; Berry Consultants, Austin, TX., Esserman LJ; University of California, San Francisco, San Francisco, CA.
Corporate Authors: I-SPY 2 Consortium
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Apr 01; Vol. 38 (10), pp. 1059-1069. Date of Electronic Publication: 2019 Feb 07.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Adaptive Clinical Trial
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO.19.01027